{"id":421,"date":"2024-02-15T14:34:00","date_gmt":"2024-02-15T14:34:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2024\/02\/15\/press-release-phase-2-data-published-in-nejm-show-potential-of-frexalimab-as-high-efficacy-therapy-in-relapsing-ms-sanofi-com\/"},"modified":"2024-02-15T14:34:00","modified_gmt":"2024-02-15T14:34:00","slug":"press-release-phase-2-data-published-in-nejm-show-potential-of-frexalimab-as-high-efficacy-therapy-in-relapsing-ms-sanofi-com","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2024\/02\/15\/press-release-phase-2-data-published-in-nejm-show-potential-of-frexalimab-as-high-efficacy-therapy-in-relapsing-ms-sanofi-com\/","title":{"rendered":"Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (sanofi.com)"},"content":{"rendered":"<p>&nbsp;<em style=\"color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px\">Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS<\/em><\/p>\n<ul class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">\n<li class=\"MuiTypography-root MuiTypography-body1 css-1ubkcfk-MuiTypography-root\" style=\"font-size: 1rem;letter-spacing: 0px;line-height: 24px;margin: 0px\">High-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain lesions<\/li>\n<li class=\"MuiTypography-root MuiTypography-body1 css-1ubkcfk-MuiTypography-root\" style=\"font-size: 1rem;letter-spacing: 0px;line-height: 24px;margin: 0px\">Phase 3 trials in relapsing MS and non-relapsing secondary progressive MS currently underway<\/li>\n<\/ul>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\"><strong>Paris, February 15, 2024.<\/strong>&nbsp;<em>The New England Journal of Medicine<\/em>&nbsp;<a class=\"elements-ds-rtmnu6\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2309439\" style=\"align-items: center;border-radius: 4px;border: none;color: #7a00e6;cursor: pointer;font-size: 1rem;letter-spacing: 0px;line-height: 24px;position: relative;width: fit-content\">published<\/a>&nbsp;results from a positive Phase 2 clinical trial demonstrating frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis (MS), corresponding to 89% and 79% reduction in new gadolinium-enhancing (GdE) T1 brain lesions at Week 12 in the high- and low-dose treatment arms compared to placebo, meeting the study\u2019s primary endpoint. Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study. Frexalimab is Sanofi\u2019s novel second-generation investigational anti-CD40L antibody that has a unique method of action with the potential to address both acute and chronic neuroinflammation in MS without causing lymphocyte depletion. These data were previously presented at Consortium of Multiple Sclerosis Centers annual meeting 2023.<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\"><strong>Patrick Vermersch, MD, PhD<\/strong><br \/>University of Lille, CHU Lille, France<br \/><em>\u201cThese published Phase 2 results for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community. Of note, at Week 12, both doses of frexalimab provided reduction of new lesions \u2013 a standard measure of active inflammation in MS \u2013 and was well-sustained over time and well tolerated, especially at the high dose of frexalimab where 96% of patients were free of new active lesions after 24 weeks of treatment.\u201d<\/em><\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">Results published in&nbsp;<em>NEJM<\/em>&nbsp;stem from the Phase 2 clinical trial that randomized 129 adults with relapsing MS to receive one of two doses of the anti-CD40L antibody frexalimab (n=52 and n=51, in the high- and low-dose treatment arms, respectively) or matching placebo (n=12 and n=14, respectively; pooled for efficacy analyses). In the high-dose treatment arm, participants received 1200 mg of frexalimab intravenously every 4 weeks with an 1800 mg loading dose. In the low-dose treatment arm, participants received 300 mg of frexalimab subcutaneously every 2 weeks with a 600 mg loading dose. After 12 weeks of treatment, both doses of frexalimab led to significant reductions in:<\/p>\n<ul class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">\n<li class=\"MuiTypography-root MuiTypography-body1 css-1ubkcfk-MuiTypography-root\" style=\"font-size: 1rem;letter-spacing: 0px;line-height: 24px;margin: 0px\">The number of new GdE T1-lesions at Week 12, providing rate ratios of 0.11 (95% CI, 0.03 to 0.38) and 0.21 (95% CI, 0.08 to 0.56), corresponding to 89% and 79% reduction in the high- and low-dose treatment arms versus placebo, the primary endpoint.<\/li>\n<li class=\"MuiTypography-root MuiTypography-body1 css-1ubkcfk-MuiTypography-root\" style=\"font-size: 1rem;letter-spacing: 0px;line-height: 24px;margin: 0px\">The number of new\/enlarging T2-lesions at Week 12, providing rate ratios of 0.08 (95% CI, 0.03 to 0.26) and 0.14 (95% CI, 0.05 to 0.41), corresponding to 92% and 86% reduction in the high- and low-dose treatment arms versus placebo, respectively, a secondary endpoint.<\/li>\n<li class=\"MuiTypography-root MuiTypography-body1 css-1ubkcfk-MuiTypography-root\" style=\"font-size: 1rem;letter-spacing: 0px;line-height: 24px;margin: 0px\">The total number of GdE T1-lesions at Week 12 providing rate ratios of 0.12 (95% CI, 0.04 to 0.36) and 0.20 (95% CI, 0.07 to 0.53) corresponding to 88% and 80% reduction, respectively, another secondary endpoint.\n<\/li>\n<\/ul>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">The effects on the primary endpoint were sustained over time across both treatment arms, with even greater reduction seen in the high-dose frexalimab treatment arm, as 96% of these study participants were free of new GdE T1-lesions at Week 24.<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">Exploratory endpoints looked at changes in the Multiple Sclerosis Impact Scale 29 (MSIS-29), a patient-reported outcome, plasma neurofilament light chain (NfL), which has been identified as a biomarker of neuroaxonal damage and MS disease activity, as well as plasma levels of CXCL13, a biomarker of inflammatory activity. Over 12 weeks of treatment, patient-reported outcome MSIS-29 physical impact scores improved significantly in participants receiving the higher dose of frexalimab. The least-square [LS] mean difference (95% confidence interval) was -7.9 (-14.7,-1.2), compared to pooled placebo. Both doses of frexalimab achieved a reduction in NfL levels relative to baseline (24% and 18% in the high- and low-dose treatment arms, respectively) and in CXCL13 levels relative to baseline (21% and 30% in the high- and low-dose treatment arms, respectively) compared to pooled placebo at Week 12.<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">Frexalimab was well-tolerated, and 125 (97%) participants completed Part A and continued to the open-label Part B. The most common adverse events (\u22655%) in any frexalimab-treated group were COVID-19 (n=5 [9.8%] in the lower-dose group; all uncomplicated cases of mild or moderate intensity) and headache (n=1 [2.0%] and n=3 [5.8%] in the low- and high-dose group, respectively).<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">Sanofi has initiated Phase 3 clinical trials of frexalimab in relapsing MS and non-relapsing secondary progressive MS.<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\"><em>About the Phase 2 trial<\/em><br \/>The Phase 2 trial was a randomized, double-blind, placebo-controlled trial evaluating frexalimab in participants with relapsing MS. Participants were randomized (4:4:1:1) to receive either high or low doses of frexalimab or matching placebo for 12 weeks (Part A). The primary endpoint was the reduction in the number of new GdE T1 MRI brain lesions at Week 12. Secondary endpoints included additional MRI-based efficacy measures as well as the safety, tolerability and pharmacokinetics of frexalimab. After Week 12, participants receiving placebo switched to respective frexalimab arms and entered the open-label Part B, which is currently ongoing.<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\"><em>About frexalimab<\/em><br \/>Frexalimab (SAR441344) is a potentially best-in-disease second generation investigational anti-CD40L antibody that blocks the costimulatory CD40\/CD40L pathway which is important for activation and function of adaptive (T and B cells) and innate (macrophages\/microglia and dendritic cells) immunity. Through this unique upstream mechanism of action, frexalimab has the potential to address both acute and chronic neuroinflammation in MS, without causing lymphocyte depletion. Sanofi is developing frexalimab under an exclusive license from ImmuNext Inc. Frexalimab is being evaluated in Phase 3 clinical trials for Multiple Sclerosis and Phase 2 clinical trials for Sjogren\u2019s Syndrome, Systemic Lupus Erythematosus, and Type 1 Diabetes, and its safety and efficacy have not been reviewed by any regulatory authority. For more information on frexalimab clinical trials, please visit www.clinicaltrials.gov.<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\"><em>About Sanofi<\/em><br \/>We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people\u2019s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.<br \/>Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY<\/p>\n<p class=\"MuiTypography-root MuiTypography-body1 css-sqijso-MuiTypography-root\" style=\"background-color: white;color: #0d0d0d;, Raleway, Roboto, sans-serif;font-size: 16px;line-height: 24px;margin: 24px 0px 0px\">See complete article, <a href=\"https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-02-15-13-00-00-2829933\" target=\"_blank\">here<\/a><\/p>\n<p><\/p>\n<div class=\"blogger-post-footer\">Visit our MS Learning Channel on YouTube:  http:\/\/www.youtube.com\/msviewsandnews <\/p>\n<\/div>\n<p><em>Source: <a href=\"http:\/\/wwwmsviewsandrelatednews.blogspot.com\/2024\/02\/press-release-phase-2-data-published-in.html\" rel=\"nofollow noopener\" target=\"_blank\">wwwmsviewsandrelatednews.blogspot.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp;Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS High-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain lesions Phase 3 trials in relapsing MS and non-relapsing secondary progressive MS currently underway Paris, February 15, 2024.&nbsp;The New England Journal of Medicine&nbsp;published&nbsp;results from a positive Phase&#8230;<\/p>\n","protected":false},"author":0,"featured_media":422,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=421"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/422"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}